

Semler to Report First Quarter 2014 Financial Results and Host Conference Call on April 22, 2014

PORTLAND, Ore., April 15, 2014 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"), an emerging medical riskassessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced that it will report first quarter 2014 financial results before the open of U.S. financial markets on April 22, 2014. Doug Murphy-Chutorian, M.D., chief executive officer of Semler will host a conference call at 10 a.m. EDT, April 22, 2014.

The conference call may be accessed by dialing +1-877-359-9508 for domestic callers and +1-224-357-2393 for international callers. Please specify to the operator that you would like to join the "Semler First Quarter 2014 Financial Results Call, conference ID#: 31468379." The conference call will be archived on Semler's website at <u>semlerscientific.com</u>.

About Semler Scientific, Inc.:

Semler Scientific, Inc. is an emerging medical risk-assessment company. Its mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services. Semler's first patented and U.S. Food and Drug Administration, or FDA, cleared product, is FloChec[™]. FloChec[™] is used in the office setting to allow providers to measure arterial blood flow in the extremities and is useful tool for internists and primary care physicians for whom it was previously impractical to conduct blood flow measurements. FloChec[™] receive@DA 510(k) clearance in February 2010, Semler began Beta testing in the third quarter of 2010, and Semler began commercially leasing FloChec[™] is now listed on the NASDAQ Capital Market under the ticker symbol "SMLR." Additional information about Semler can be found at <u>semlerscientific.com</u>.

CONTACT:

Susan A. Noonan S.A. Noonan Communications susan@sanoonan.com 212 966 3650

SOURCE Semler Scientific, Inc.

News Provided by Acquire Media